Open AccessIn vitro activity and susceptibility to hydrolysis of S-1006
Author(s) -
Harold C. Neu,
JianWei Gu,
Wei Fang,
Nai-Xun Chin
Publication year - 1992
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.36.6.1336
Subject(s) - providencia , microbiology and biotechnology , enterobacter , proteus vulgaris , citrobacter freundii , enterobacter cloacae , haemophilus influenzae , citrobacter , serratia , staphylococcus aureus , biology , enterobacteriaceae , cephalosporin , proteus , streptococcus pneumoniae , bacteria , escherichia coli , pseudomonas , antibiotics , biochemistry , genetics , gene
The in vitro activity of S-1006, the active component of a new orally absorbed cephalosporin, S-1108, inhibited 90% of Staphylococcus aureus isolates at less than or equal to 2 micrograms/ml, 90% of group A, B, C, F, and G streptococci and Streptococcus pneumoniae isolates at less than or equal to 0.12 microgram/ml, and all Haemophilus influenzae isolates at less than or equal to 0.06 microgram/ml. Although 50% of the members of the family Enterobacteriaceae were inhibited by less than or equal to 2 micrograms of S-1006 per ml, Enterobacter spp. and Citrobacter freundii resistant to ceftriaxone were resistant to S-1006. The MICs of S-1006 for approximately 20% of Providencia, Proteus vulgaris, and Serratia isolates were 4 micrograms/ml. S-1006 was hydrolyzed by the plasmid TEM-3, TEM-5, PSE-1, and PSE-4 beta-lactamases and by the chromosomal beta-lactamase of Enterobacter and Morganella spp. and P. vulgaris.